Key facts
- Notable investors include Tech Incubator Program for Startup, Medytox Venture Investment, Reventures, Rising S Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Frinsulin Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Frinsulin Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Frinsulin Biotech
Operator of a medical firm intended to develop a diabetes drug to improve insulin resistance. The company is researching new drugs based on the mechanism of action for insulin resistance, enabling medical practitioners to help patients treat metabolic diseases caused by insulin.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2017
- Employees
- 5
- Website
- frinsulin.com/
- Ownership
- Privately Held (backing)
Frinsulin Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Frinsulin Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Frinsulin Biotech in its N-PORT filings yet. We sweep new filings monthly.